• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Biopharma R&D Funding Has Rebounded But Clinical Trial Starts Slowed Down in 2023, Says...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 22, 2024 at 11:33: PM
via Research and development (R&D) funding — which include initial public offerings (IPOs) in IQVIA’s reckoning — by biopharma companies grew to $72 billion in 2023, an 18% increase from $61 billion in 2022, although $62 billion less than $134 billion in 2020, according to the IQVIA Institute for Human Data Science “Global Trends in R&D 2024” report.

article source
 




Top Bottom
Back
Quote